To evaluate MTX-101 effects in a highly inflammatory setting in vivo, we tested MTX-101 in an aggressive, systemic inflammatory humanized murine model of acute graft-versus-host disease (GvHD) that engrafts human T cells, including CD8 Tregs (Figure 5A) (33). Here, CD8A is linked to graft versus host disease.